Elizabeth E. Evans

783 total citations
31 papers, 390 citations indexed

About

Elizabeth E. Evans is a scholar working on Cellular and Molecular Neuroscience, Oncology and Immunology. According to data from OpenAlex, Elizabeth E. Evans has authored 31 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cellular and Molecular Neuroscience, 12 papers in Oncology and 11 papers in Immunology. Recurrent topics in Elizabeth E. Evans's work include Axon Guidance and Neuronal Signaling (17 papers), CAR-T cell therapy research (5 papers) and HER2/EGFR in Cancer Research (5 papers). Elizabeth E. Evans is often cited by papers focused on Axon Guidance and Neuronal Signaling (17 papers), CAR-T cell therapy research (5 papers) and HER2/EGFR in Cancer Research (5 papers). Elizabeth E. Evans collaborates with scholars based in United States, United Kingdom and Germany. Elizabeth E. Evans's co-authors include Maurice Zauderer, Ernest Smith, Mark Paris, Alan S. Jonason, Terrence L. Fisher, Alan Howell, Christine Reilly, Crystal Mallow, Laurie A. Winter and Sebold Torno and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Elizabeth E. Evans

30 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth E. Evans United States 10 159 136 119 113 37 31 390
Miho Oyasu Japan 11 327 2.1× 161 1.2× 99 0.8× 112 1.0× 71 1.9× 17 591
Christine Reilly United States 9 145 0.9× 216 1.6× 65 0.5× 120 1.1× 38 1.0× 14 405
Patricia Fernández‐Nogueira Spain 9 183 1.2× 108 0.8× 112 0.9× 42 0.4× 40 1.1× 13 357
Arend H. Sikkema Netherlands 9 196 1.2× 46 0.3× 50 0.4× 72 0.6× 37 1.0× 12 340
Mauro Togni Germany 11 134 0.8× 54 0.4× 98 0.8× 241 2.1× 51 1.4× 19 545
Celia López‐Menéndez Spain 11 323 2.0× 114 0.8× 80 0.7× 56 0.5× 67 1.8× 13 481
Marta González-García Spain 6 311 2.0× 90 0.7× 86 0.7× 82 0.7× 23 0.6× 11 452
Qing Ouyang China 13 279 1.8× 84 0.6× 87 0.7× 64 0.6× 29 0.8× 19 471
Janaki Veeraraghavan United States 4 134 0.8× 137 1.0× 191 1.6× 90 0.8× 15 0.4× 6 407
Daniele Alaimo United States 10 186 1.2× 60 0.4× 237 2.0× 111 1.0× 60 1.6× 19 591

Countries citing papers authored by Elizabeth E. Evans

Since Specialization
Citations

This map shows the geographic impact of Elizabeth E. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth E. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth E. Evans more than expected).

Fields of papers citing papers by Elizabeth E. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth E. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth E. Evans. The network helps show where Elizabeth E. Evans may publish in the future.

Co-authorship network of co-authors of Elizabeth E. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth E. Evans. A scholar is included among the top collaborators of Elizabeth E. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth E. Evans. Elizabeth E. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feigin, Andrew, Elizabeth E. Evans, Terrence L. Fisher, & Maurice Zauderer. (2025). Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases. Expert Opinion on Investigational Drugs. 34(3). 109–119. 1 indexed citations
2.
Steuer, Conor, Elizabeth E. Evans, Terrence L. Fisher, et al.. (2025). Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.. Journal of Clinical Oncology. 43(16_suppl). 103–103.
3.
Greengard, Emily, Robin Williams, Branden S. Moriarity, et al.. (2024). A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. 71(6). e30938–e30938. 2 indexed citations
4.
Zauderer, Maurice & Elizabeth E. Evans. (2023). Conclusions of the SIGNAL study in Huntington and implications for treatment of other slowly progressive neurodegenerative diseases. Clinical and Translational Medicine. 13(2). e1169–e1169. 6 indexed citations
5.
6.
Evans, Elizabeth E., Vikas Mishra, Crystal Mallow, et al.. (2022). Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. Journal of Neuroinflammation. 19(1). 200–200. 21 indexed citations
7.
Veerapen, Natacha, Leandro J. Carreño, Jinghang Zhang, et al.. (2021). Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Research. 81(7). 1788–1801. 9 indexed citations
8.
Yang, Yuchen, et al.. (2020). Spontaneous Tumor Lysis Syndrome in an Adenocarcinoma of Unknown Origin. Cureus. 12(12). e12169–e12169. 6 indexed citations
9.
10.
Lowe, Michael, Brian M. Olson, Anthony P. Martinez, et al.. (2020). Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10061–10061. 2 indexed citations
11.
Das, Rupali, Peng Guan, Susan J. Wiener, et al.. (2019). Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein. Blood Advances. 3(5). 813–824. 12 indexed citations
12.
Clavijo, Paúl E., Jay Friedman, Yvette Robbins, et al.. (2018). Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunology Research. 7(2). 282–291. 40 indexed citations
13.
Evans, Elizabeth E., Romain Paillot, & María R. López-Álvarez. (2018). A comprehensive analysis of e-CAS cell line reveals they are mouse macrophages. Scientific Reports. 8(1). 8237–8237. 2 indexed citations
14.
Evans, Elizabeth E., Alan S. Jonason, Holm Bußler, et al.. (2015). Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research. 3(6). 689–701. 88 indexed citations
15.
Fisher, Terrence L., Christine Reilly, Laurie A. Winter, et al.. (2015). Generation and preclinical characterization of an antibody specific for SEMA4D. mAbs. 8(1). 150–162. 36 indexed citations
16.
Evans, Elizabeth E., Mark Paris, Ernest Smith, & Maurice Zauderer. (2015). Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D. OncoImmunology. 4(12). e1054599–e1054599. 14 indexed citations
17.
Evans, Elizabeth E., Siwen Hu‐Lieskovan, Holm Bußler, et al.. (2015). Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations. Journal for ImmunoTherapy of Cancer. 3(S2). 3 indexed citations
18.
Katz, Elad, Andrew H. Sims, Dana Faratian, et al.. (2010). A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. British Journal of Cancer. 103(3). 401–410. 60 indexed citations
19.
Evans, Elizabeth E., Alan S. Jonason, Mark Paris, et al.. (2006). C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Molecular Cancer Therapeutics. 5(11). 2919–2930. 43 indexed citations
20.
Smith, Ernest, Elizabeth E. Evans, Loretta Mueller, et al.. (2001). Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens. Nature Medicine. 7(8). 967–972. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miho Oyasu Breakdown of academic impact, for papers by Christine Reilly Breakdown of academic impact, for papers by Patricia Fernández‐Nogueira Breakdown of academic impact, for papers by Arend H. Sikkema Breakdown of academic impact, for papers by Mauro Togni Breakdown of academic impact, for papers by Celia López‐Menéndez Breakdown of academic impact, for papers by Marta González-García Breakdown of academic impact, for papers by Qing Ouyang Breakdown of academic impact, for papers by Janaki Veeraraghavan Breakdown of academic impact, for papers by Daniele Alaimo
Rankless by CCL
2026